

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, 5/10, 1/21, C07K 14/47, 16/18, A61K 38/17, C12Q 1/68		A3	(11) International Publication Number: WO 00/05374
			(43) International Publication Date: 3 February 2000 (03.02.00)
(21) International Application Number: PCT/US99/16637 (22) International Filing Date: 21 July 1999 (21.07.99) (30) Priority Data: 60/093,827 22 July 1998 (22.07.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/093,827 (CIP) Filed on 22 July 1998 (22.07.98) (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). BAUGHN,			(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 15 June 2000 (15.06.00)
(54) Title: MOLECULES ASSOCIATED WITH CELL PROLIFERATION			
(57) Abstract <p>The invention provides human molecules associated with cell proliferation (MACP) and polynucleotides which identify and encode MACP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of MACP.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

Intern al Application No

PCT/US 99/16637

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N5/10 C12N1/21 C07K14/47 C07K16/18
A61K38/17 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 98 12327 A (BAER RICHARD ;BOWCOCK ANNE M (US); UNIV TEXAS (US)) 26 March 1998 (1998-03-26) BE2: SeqIdNo.40: 99.7% identity in 345 bp overlap with SeqIdNo.6 / SeqIdNo.41: 98.8% identity in 80 aa overlap with SeqIdNo.1 --- -/-</p>	1-14,17, 19-21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

11 January 2000

Date of mailing of the international search report

19. 04. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lonnoy, 0

INTERNATIONAL SEARCH REPORT

Intern al Application No
PCT/US 99/16637

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>TAHIRA T ET AL: "Activation of human c-raf-1 by replacing the N-terminal region with different sequences" NUCLEIC ACIDS RESEARCH., vol. 15, no. 12, 25 June 1987 (1987-06-25), pages 4809-4820, XP002127228 99.7% identity in 322bp overlap with SeqIdNo.6 -& DATABASE EMHUM3 [Online] E.M.B.L. Databases Accession Number: X06409, 2 April 1988 (1988-04-02) TAHIRA T ET AL: "Human mRNA fragment for activated c-raf-1 (exons 8-17)" XP002127230 99.7% identity in 322bp overlap with SeqIdNo.6 abstract</p>	1-14,17, 19-21
X	<p>PRIMIANO T ET AL: "Isolation of cDNAs representing dithiolethione-responsive genes" CARCINOGENESIS, vol. 17, no. 11, November 1996 (1996-11), pages 2297-2303, XP002127229 DIG-2: 92.4% identity in 79 aa overlap with SeqIdNo.1 -----</p>	1-14,17, 19-21

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 16637

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
See FURTHER INFORMATION SHEET
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-21 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99/16637

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-21 (all partially)

A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting SeqIdNo.1 and fragments thereof; a substantially purified variant having at least 90% amino acid identity to said amino acid sequence; An isolated and purified polynucleotide encoding said polypeptide; an isolated and purified polynucleotide having at least 90% identity to said polynucleotide; an isolated and purified polynucleotide hybridising to said polynucleotide; an isolated and purified polynucleotide complementary to said polynucleotide; an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SeqIdNo.6 and fragments thereof; corresponding recombinant DNA products and methods; A purified antibody to said polypeptide; a purified agonist to said polypeptide; a purified antagonist to said polypeptide; A pharmaceutical composition comprising said polypeptide, or said antagonist; A diagnostic method employing said polynucleotide.

2. Claims: 1-21 (all partially)

As for subject 1 but respectively relating to SeqIdNo.2 and SeqIdNo.7

3. Claims: 1-21 (all partially)

As for subject 1 but respectively relating to SeqIdNo.3 and SeqIdNo.8

4. Claims: 1-21 (all partially)

As for subject 1 but respectively relating to SeqIdNo.4 and SeqIdNo.9

5. Claims: 1-21 (all partially)

As for subject 1 but respectively relating to SeqIdNo.5 and SeqIdNo.10

INTERNATIONAL SEARCH REPORT

1. Information on patent family members

Internal Application No

PCT/US 99/16637

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9812327 A	26-03-1998	AU 4586697 A	14-04-1998
